Financial Results (Q2 FY2022) - QoQ comparison

Laurus Labs has reported a total income of Rs. 1206.31 crore during the period ended September 30, 2021, as compared to Rs. 1284.35 crore during the period ended June 30, 2021, a decline of 6.8 per cent.

The company has posted a net profit of Rs. 201.90 crore for the period ended September 30, 2021, as against a net profit of Rs. 241.39 crore for the period ended June 30, 2021, a decline of 16.36 per cent.

Financial Results (Q2 FY2022) - YoY comparison

The company has reported a total income of Rs. 1206.31 crore during the period ended September 30, 2021, as compared to Rs.1143.96 crores during the period ended September 30, 2020, an increase of 5.45 per cent.

The company has posted a net profit of Rs.201.90 crore for the period ended September 30, 2021, as against a net profit of Rs.242.27 crore for the period ended September 30, 2020, a decline of 16.66 per cent.

Financial Results (Half Year Ended FY2022) - YoY comparison

The company has reported a total income of Rs.2490.66 crore during the 6 months ended September 30, 2021, as compared to Rs.2125.37 crore during the 6 months ended September 30, 2020, an increase of 17.19 per cent.

The company has posted a net profit of Rs.443.29 crore for the 6 months ended September 30, 2021, as against a net profit of Rs.414.05 crore for the 6 months ended September 30, 2020, an increase of 7.06 per cent.

Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “The financial performance of the quarter has been tepid and driven by sales growth. While our profits growth had been modest for the quarter, we clocked healthy growth for H1 FY22. We continue to sharpen our execution across our core business despite challenging times. Our sustained traction in FDF and CDMO business was a key driver of the growth. We are focusing on positioning our businesses for sustainable long term growth. “Importantly, I am pleased to share that recently our Laurus Synthesis Pvt Ltd (LSPL) unit has executed a multi-year partnership deal with a leading Global Life science company. The deal entails complete drug development and manufacturing of a portfolio of niche APIs. Under the agreement, LSPL will set up a dedicated manufacturing facility to manufacture and supply APIs. We believe the deal demonstrates our technological capabilities and will mark a significant step forward in our evolution as a valuable partner to the global pharmaceutical industry. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain.”